Rezon Bio shares its perspectives on how CDMOs must evolve to meet the rising demands for speed, quality and cost-efficiency in today’s biologics market.
The biologics market is changing. What was once a race for innovation at any cost is now a discipline of efficiency. Speed, quality and cost are no longer trade-offs; they must be delivered in balance. For CDMOs, this means rethinking how projects are developed, transferred and commercialized and how partnerships are structured for long-term success. At the same time, global supply chains are being re-evaluated. Regionalization, reliability and trust are increasingly valued alongside technical capability. Clients are asking not only if CDMOs can manufacture a product, but also if they are willing to stand by them as pressures increase and markets evolve.
In a recent article published by the European Biopharmaceutical Review, Rezon Bio outlines how it was established to meet the evolving demands of today’s biologics landscape. Emerging from the biosimilar division of Polpharma Biologics, Rezon Bio was launched as a focused and agile mid-sized CDMO, backed by years of commercial experience, world-class infrastructure and a strong regulatory track record. With two state-of-the-art facilities in Gdańsk and Warsaw-Duchnice, the company is purpose-built to support biotech and biopharmaceutical clients across the biologics development and manufacturing journey, combining technical expertise with a pragmatic, client-centric approach.
